Gonadotropin-releasing hormone analog therapy failed to improve predicted final height in two children with central precocious puberty and microcephalus.
Long-acting gonadotropin-releasing hormone (GnRH) analog treatment for central precocious puberty (CPP) suppresses excessive bone maturation by inhibiting the pituitary-gonadal axis, and usually assures favorable results for growth potential. Recently, we encountered two children with CPP and microcephalus in whom GnRH analog therapy arrested pubertal development, but could not suppress bone age maturation effectively. Eventually, their final height deteriorated rather than improved. The reason why these two cases did not respond to GnRH analog therapy remains unknown. However, microcephalus and minor cerebral anomalies may have some links to deterioration of final height. Our cases suggest that careful evaluation will be required especially for CPP with microcephalus throughout treatment with GnRH analog.
Okuhara
K
K
Department of Pediatrics, Hokkaido University School of Medicine, Sapporo, Japan.
Tajima
T
T
Abe
S
S
Satoh
K
K
Nakae
J
J
Shinohara
N
N
Fujieda
K
K
D000293:Adolescent; D001827:Body Height / Q000187:drug effects*; D002675:Child, Preschool; D005260:Female; D005544:Forecasting; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008831:Microcephaly / Q000150:complications*; D011629:Puberty, Precocious / Q000150:complications* / Q000188:drug therapy*; D017211:Treatment Failure
D007987:Gonadotropin-Releasing Hormone